MedTrace Logo

Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients

NCT01109147 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2014-04-09

Study results available
· View outcomes & findings →

Summary

After an initial screening visit, including an assessment of psychiatric disorders, patients stabilized on antipsychotic medication (aripiprazole or risperidone) for at least 6 weeks and control subjects will undergo an assessment using functional magnetic resonance imaging (fMRI) of the differences of patterns of brain activation during an emotional task

Conditions

  • Schizophrenia, Undifferentiated Type

Interventions

OTHER

Imagery

All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.

GENETIC

pharmacogenetic sampling

A pharmacogenetic sample will be done with an additional consentment.

Sponsors & Collaborators

  • Qualissima

    lead OTHER

Principal Investigators

  • Olivier Blin, professor · study coordinator

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2013-01-31
Completion
2013-05-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01109147 on ClinicalTrials.gov